Global Personalized Cancer Medicine Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Personalized Cancer Medicine Market Research Report 2024
Personalized cancer medicine, also known as targeted therapies or precision medicines, are medications designed to specifically target the unique genetic or molecular characteristics of an individual patient's cancer. These drugs are a central component of personalized cancer medicine and are chosen based on the genomic and molecular profiling of the patient's tumor.
ImmunotherapiesWhile not traditional targeted therapies, immunotherapies like immune checkpoint inhibitors are another form of personalized cancer treatment. These drugs enhance the patient's immune system to recognize and attack cancer cells, and they can be tailored to patients based on their tumor's molecular characteristics.
Personalized cancer treatment drugs have revolutionized cancer care by allowing oncologists to tailor treatment plans to the individual characteristics of each patient's cancer. This approach holds great promise for improving outcomes and reducing the side effects associated with traditional cancer treatments. However, ongoing research and advancements are needed to expand the repertoire of targeted therapies and ensure that they are accessible to more cancer patients.
According to Mr Accuracy reports’s new survey, global Personalized Cancer Medicine market is projected to reach US$ 350430 million in 2029, increasing from US$ 161690 million in 2022, with the CAGR of 12.5% during the period of 2024 to 2029.
In the global market, the core manufacturers of Precision Cancer Medicine (Personalised Cancer Medicine) are AbbVie, Johnson & Johnson, Novartis, and others. The top three players within this industry account for about 30% of the market share. North America, Europe, and Asia Pacific are the major manufacturing regions for this product, with North America accounting for over 50% of the global market share. The product can be classified on the basis of treatment into immunotherapy and targeted therapy drugs. The product is widely used in the treatment of lung, breast, prostate, blood and other cancers.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Personalized Cancer Medicine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
GSK
Exelixis
Regeneron
Innovent
Hengrui Medicine
Segment by Method
Cancer Immunotherapy
Targeted Therapy
Lung Cancer
Breast Cancer
Prostate Cancer
Blood-related Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Personalized Cancer Medicine report covers below items
Chapter 1Product Basic Information (Definition, Method and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Method Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
ImmunotherapiesWhile not traditional targeted therapies, immunotherapies like immune checkpoint inhibitors are another form of personalized cancer treatment. These drugs enhance the patient's immune system to recognize and attack cancer cells, and they can be tailored to patients based on their tumor's molecular characteristics.
Personalized cancer treatment drugs have revolutionized cancer care by allowing oncologists to tailor treatment plans to the individual characteristics of each patient's cancer. This approach holds great promise for improving outcomes and reducing the side effects associated with traditional cancer treatments. However, ongoing research and advancements are needed to expand the repertoire of targeted therapies and ensure that they are accessible to more cancer patients.
According to Mr Accuracy reports’s new survey, global Personalized Cancer Medicine market is projected to reach US$ 350430 million in 2029, increasing from US$ 161690 million in 2022, with the CAGR of 12.5% during the period of 2024 to 2029.
In the global market, the core manufacturers of Precision Cancer Medicine (Personalised Cancer Medicine) are AbbVie, Johnson & Johnson, Novartis, and others. The top three players within this industry account for about 30% of the market share. North America, Europe, and Asia Pacific are the major manufacturing regions for this product, with North America accounting for over 50% of the global market share. The product can be classified on the basis of treatment into immunotherapy and targeted therapy drugs. The product is widely used in the treatment of lung, breast, prostate, blood and other cancers.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Personalized Cancer Medicine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
GSK
Exelixis
Regeneron
Innovent
Hengrui Medicine
Segment by Method
Cancer Immunotherapy
Targeted Therapy
Segment by Application
Lung Cancer
Breast Cancer
Prostate Cancer
Blood-related Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Personalized Cancer Medicine report covers below items
Chapter 1Product Basic Information (Definition, Method and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Method Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices